Compare Dyne Therapeutics Inc. Common Stock (DYN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while State Street SPDR S&P Biotech ETF trades at $147.08 (market cap $10.27B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.6× Dyne Therapeutics Inc. Common Stock's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| DYN | XBI | |
|---|---|---|
Market Cap | $2.86B | $10.27B |
Volume | 3,341,579 | 9,751,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $169.55 |
52-Week Low | $14.60 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
